Log in | Register

Challenges in severe community-acquired pneumonia: a point-of-view review

Antoni Torres| James D. Chalmers| Charles S. Dela Cruz| Cristina Dominedò| Marin Kollef| Ignacio Martin-Loeches| Michael Niederman| Richard G. Wunderink
Review
Volume 45, Issue 2 / February , 2019

Pages 159 - 171

Abstract

Purpose

Severe community-acquired pneumonia (SCAP) is still associated with substantial morbidity and mortality. In this point-of-view review paper, a group of experts discuss the main controversies in SCAP: the role of severity scores to guide patient settings of care and empiric antibiotic therapy; the emergence of pathogens outside the core microorganisms of CAP; viral SCAP; the best empirical treatment; septic shock as the most lethal complication; and the need for new antibiotics.

Methods

For all topics, the authors describe current controversies and evidence and provide recommendations and suggestions for future research. Evidence was based on meta-analyses, most recent RCTs and recent interventional or observational studies. Recommendations were reached by consensus of all the authors.

Results and conclusions

The IDSA/ATS criteria remain the most pragmatic tool to predict ICU admission. The authors recommend a combination of a beta-lactam/beta-lactamase inhibitor or a third G cephalosporin plus a macrolide in most SCAP patients, and to empirically cover PES (P. aeruginosa, extended spectrum beta-lactamase producing Enterobacteriaceae, methicillin-resistant S. aureus) pathogens when at least two specific risk factors are present. In patients with influenza CAP, the authors recommend the use of oseltamivir and avoidance of the use of steroids. Corticosteroids can be used in case of refractory shock and high systemic inflammatory response.

Keywords

References

  1. Laporte L, Hermetet C, Jouan Y, Gaborit C, Rouve E, Shea KM, Si-Tahar M, Dequin PF, Grammatico-Guillon L, Guillon A (2018) Ten-year trends in intensive care admissions for respiratory infections in the elderly. Ann Intensive Care 8:84
    • View reference on publisher's website
  2. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L (2015) Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:415–427
    • View reference on publisher's website
  3. Cilloniz C, Dominedo C, Garcia-Vidal C, Torres A (2018) Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care 24:531–539
  4. Montull B, Menendez R, Torres A, Reyes S, Mendez R, Zalacain R, Capelastegui A, Rajas O, Borderias L, Martin-Villasclaras J, Bello S, Alfageme I, Rodriguez de Castro F, Rello J, Molinos L, Ruiz-Manzano J (2016) Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. PLoS ONE 11:e0145929
    • View reference on publisher's website
  5. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG (2006) Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 10(Suppl 2):S1
    • View reference on publisher's website
  6. Ranzani OT, Prina E, Menendez R, Ceccato A, Cilloniz C, Mendez R, Gabarrus A, Barbeta E, Bassi GL, Ferrer M, Torres A (2017) New sepsis definition (sepsis-3) and community-acquired pneumonia mortality. A validation and clinical decision-making study. Am J Respir Crit Care Med 196:1287–1297
    • View reference on publisher's website
  7. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratala J, Chang FY, Charles PG, Diaz AA, Dominguez J, Ehara N, Endeman H, Falco V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Marekovic I, Masia M, Matta MA, Miro O, Murdoch DR, Nuermberger E, Paolini R, Perello R, Snijders D, Plecko V, Sorde R, Stralin K, van der Eerden MM, Vila-Corcoles A, Watt JP (2013) Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE 8:e60273
    • View reference on publisher's website
  8. Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, Niederman MS, Torres A (2016) Community-acquired pneumonia due to multidrug- and non-multidrug-resistant pseudomonas aeruginosa. Chest 150:415–425
    • View reference on publisher's website
  9. Garnacho-Montero J, Barrero-Garcia I, Gomez-Prieto MG, Martin-Loeches I (2018) Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther 16:667–677
    • View reference on publisher's website
  10. Pereira JM, Goncalves-Pereira J, Ribeiro O, Baptista JP, Froes F, Paiva JA (2018) Impact of antibiotic therapy in severe community-acquired pneumonia: data from the Infauci study. J Crit Care 43:183–189
    • View reference on publisher's website
  11. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372:1312–1323
    • View reference on publisher's website
  12. Lee JH, Kim HJ, Kim YH (2017) Is beta-lactam plus macrolide more effective than beta-lactam plus fluoroquinolone among patients with severe community-acquired pneumonia?: a systemic review and meta-analysis. J Korean Med Sci 32:77–84
    • View reference on publisher's website
  13. Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menendez R, Mensa J, Torres A (2015) Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 12:153–160
    • View reference on publisher's website
  14. Waterer G (2017) Severity scores and community-acquired pneumonia. Time to move forward. Am J Respir Crit Care Med 196:1236–1238
    • View reference on publisher's website
  15. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, Hill AT (2011) Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 37:1409–1420
  16. Waterer GW, Self WH, Courtney DM, Grijalva CG, Balk RA, Girard TD, Fakhran SS, Trabue C, McNabb P, Anderson EJ, Williams DJ, Bramley AM, Jain S, Edwards KM, Wunderink RG (2018) In-hospital deaths among adults with community-acquired pneumonia. Chest 154:628–635
    • View reference on publisher's website
  17. Chalmers JD, Taylor JK, Mandal P, Choudhury G, Singanayagam A, Akram AR, Hill AT (2011) Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 53:503–511
    • View reference on publisher's website
  18. Charles PG, Davis JS, Grayson ML (2009) Rocket science and the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines for severe community-acquired pneumonia. Clin Infect Dis 48:1796 (author reply 1796–1797)
    • View reference on publisher's website
  19. Wunsch H, Angus DC, Harrison DA, Linde-Zwirble WT, Rowan KM (2011) Comparison of medical admissions to intensive care units in the United States and United Kingdom. Am J Respir Crit Care Med 183:1666–1673
    • View reference on publisher's website
  20. Lim HF, Phua J, Mukhopadhyay A, Ngerng WJ, Chew MY, Sim TB, Kuan WS, Mahadevan M, Lim TK (2014) IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. Eur Respir J 43:852–862
    • View reference on publisher's website
  21. Salih W, Schembri S, Chalmers JD (2014) Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J 43:842–851
    • View reference on publisher's website
  22. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Grayson ML (2008) SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 47:375–384
    • View reference on publisher's website
  23. Ebrahimi F, Giaglis S, Hahn S, Blum CA, Baumgartner C, Kutz A, van Breda SV, Mueller B, Schuetz P, Christ-Crain M, Hasler P (2018) Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. Eur Respir J 51:1701389
    • View reference on publisher's website
  24. Mendez R, Menendez R, Cilloniz C, Amara-Elori I, Amaro R, Gonzalez P, Posadas T, Gimeno A, Espana PP, Almirall J, Torres A (2018) Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med 198:370–378
    • View reference on publisher's website
  25. Singanayagam A, Chalmers JD (2013) Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med 1:653–662
    • View reference on publisher's website
  26. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72
    • View reference on publisher's website
  27. Webb BJ, Dascomb K, Stenehjem E, Dean N (2015) Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. Respir Med 109:1–10
    • View reference on publisher's website
  28. Hariri G, Tankovic J, Boelle PY, Dubee V, Leblanc G, Pichereau C, Bourcier S, Bige N, Baudel JL, Galbois A, Ait-Oufella H, Maury E (2017) Are third-generation cephalosporins unavoidable for empirical therapy of community-acquired pneumonia in adult patients who require ICU admission? A retrospective study. Ann Intensive Care 7:35
    • View reference on publisher's website
  29. Rodrigo-Troyano A, Sibila O (2017) The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirology (Carlton, Vic) 22:1288–1299
    • View reference on publisher's website
  30. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y (2013) Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188:985–995
    • View reference on publisher's website
  31. Maruyama T, Fujisawa T, Ishida T, Ito A, Oyamada Y, Fujimoto K, Yoshida M, Maeda H, Miyashita N, Nagai H, Imamura Y, Shime N, Suzuki S, Amishima M, Higa F, Kobayashi H, Suga S, Tsutsui K, Kohno S, Brito V, Niederman MS (2018) A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter- cohort study using risk factors for multidrug resistant pathogens to select initial empiric therapy. Clin Infect Dis
  32. Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, Arita M (2017) Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: evaluation of PES pathogens. J Infect Chemother 23:23–28
    • View reference on publisher's website
  33. Torres A, Cilloniz C, Ferrer M, Gabarrus A, Polverino E, Villegas S, Marco F, Mensa J, Menendez R, Niederman M (2015) Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J 45:1353–1363
    • View reference on publisher's website
  34. Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S (2018) Burdenand risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 52:1701190
    • View reference on publisher's website
  35. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI (2016) Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis 16:1364–1376
    • View reference on publisher's website
  36. Martin-Loeches I, Schultz MJ, Vincent JL, Alvarez-Lerma F, Bos LD, Sole-Violan J, Torres A, Rodriguez A (2017) Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 43:48–58
  37. Piralla A, Rovida F, Girello A, Premoli M, Mojoli F, Belliato M, Braschi A, Iotti G, Pariani E, Bubba L, Zanetti AR, Baldanti F (2017) Frequency of respiratory virus infections and next-generation analysis of influenza A/H1N1pdm09 dynamics in the lower respiratory tract of patients admitted to the ICU. PLoS ONE 12:e0178926
    • View reference on publisher's website
  38. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 132:Cd008965
  39. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ (2014) Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2545
    • View reference on publisher's website
  40. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (2014) Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2547
    • View reference on publisher's website
  41. Dobson J, Whitley RJ, Pocock S, Monto AS (2015) Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet (London, England) 385:1729–1737
    • View reference on publisher's website
  42. Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A (2018) Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Res 157:38–46
    • View reference on publisher's website
  43. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrus A, Sellares J, Restrepo MI, Anzueto A, Niederman MS, Agusti C (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:677–686
    • View reference on publisher's website
  44. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M (2017) Corticosteroids for pneumonia. Cochrane Database Syst Rev 12:Cd007720
  45. Mc Mahon A, Martin-Loeches I (2017) The pharmacological management of severe influenza infection—’existing and emerging therapies’. Expert Rev Clin Pharmacol 10:81–95
    • View reference on publisher's website
  46. Moreno G, Rodriguez A, Reyes LF, Gomez J, Sole-Violan J, Diaz E, Bodi M, Trefler S, Guardiola J, Yebenes JC, Soriano A, Garnacho-Montero J, Socias L, Del Valle Ortiz M, Correig E, Marin-Corral J, Vallverdu-Vidal M, Restrepo MI, Torres A, Martin-Loeches I (2018) Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 44:1470–1482
  47. Martin-Loeches I, Soares M, Torres A (2016) Neces-SARI-ly? Intensive Care Med 42:928–930
  48. Marty FM, Vidal-Puigserver J, Clark C, Gupta SK, Merino E, Garot D, Chapman MJ, Jacobs F, Rodriguez-Noriega E, Husa P, Shortino D, Watson HA, Yates PJ, Peppercorn AF (2017) Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 5:135–146
    • View reference on publisher's website
  49. Murphy TF (2008) Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value. Clin Infect Dis 47(Suppl 3):S145–S149
    • View reference on publisher's website
  50. Kmietowicz Z (2014) Critics attack chief medical officer’s advice to use antivirals for flu. BMJ 348:g1496
    • View reference on publisher's website
  51. Leroy O, Saux P, Bedos JP, Caulin E (2005) Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128:172–183
    • View reference on publisher's website
  52. Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, Liapikou A, Blasi F, Torres A (2018) Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE 13:e0191721
    • View reference on publisher's website
  53. De la Calle C, Ternavasio-de la Vega HG, Morata L, Marco F, Cardozo C, Garcia-Vidal C, Del Rio A, Cilloniz C, Torres A, Martinez JA, Mensa J, Soriano A (2018) Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infect 76:342–347
    • View reference on publisher's website
  54. Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A (2014) beta-Lactam monotherapy vs. beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Internal Med 174:1894–1901
    • View reference on publisher's website
  55. Anderson R, Steel HC, Cockeran R, Smith AM, von Gottberg A, de Gouveia L, Brink A, Klugman KP, Mitchell TJ, Feldman C (2007) Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 59:224–229
    • View reference on publisher's website
  56. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE (2015) Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372:1114–1125
    • View reference on publisher's website
  57. Gershengorn HB, Keene A, Dzierba AL, Wunsch H (2015) The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia. Clin Infect Dis 60:e66–e79
    • View reference on publisher's website
  58. Griffin AT, Peyrani P, Wiemken TL, Ramirez JA, Arnold FW (2013) Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. Infection 41:517–523
    • View reference on publisher's website
  59. Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J (2007) Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 45:315–321
    • View reference on publisher's website
  60. Sicot N, Khanafer N, Meyssonnier V, Dumitrescu O, Tristan A, Bes M, Lina G, Vandenesch F, Vanhems P, Etienne J, Gillet Y (2013) Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia–results of a prospective observational study. Clin Microb Infect 19:E142–E148
    • View reference on publisher's website
  61. File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D (2010) Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51:1395–1405
    • View reference on publisher's website
  62. Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL (2018) Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 320:984–994
    • View reference on publisher's website
  63. Walden AP, Clarke GM, McKechnie S, Hutton P, Gordon AC, Rello J, Chiche JD, Stueber F, Garrard CS, Hinds CJ (2014) Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care 18:R58
    • View reference on publisher's website
  64. Hadfield J, Bennett L (2018) Determining best outcomes from community-acquired pneumonia and how to achieve them. Respirology (Carlton, Vic) 23:138–147
    • View reference on publisher's website
  65. Siow WT, Koay ES, Lee CK, Lee HK, Ong V, Ngerng WJ, Lim HF, Tan A, Tang JW, Phua J (2016) The use of polymerase chain reaction amplification for the detection of viruses and bacteria in severe community-acquired pneumonia. Respir Int Rev Thorac Dis 92:286–294
  66. Seymour CW, Kahn JM, Martin-Gill C, Callaway CW, Yealy DM, Scales D, Angus DC (2017) Delays from first medical contact to antibiotic administration for sepsis. Crit Care Med 45:759–765
    • View reference on publisher's website
  67. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377
  68. Howell MD, Davis AM (2018) Management of ARDS in adults. JAMA 319:711–712
    • View reference on publisher's website
  69. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, Joyce C, Li Q, McArthur C, Perner A, Rhodes A, Thompson K, Webb S, Myburgh J (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797–808
    • View reference on publisher's website
  70. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, Francois B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohe J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378:809–818
    • View reference on publisher's website
  71. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124
    • View reference on publisher's website
  72. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
    • View reference on publisher's website
  73. Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, Goldmann A, Kuhn SO, Huter L, Meier-Hellmann A, Nierhaus A, Kluge S, Lehmke J, Loeffler M, Oppert M, Resener K, Schadler D, Schuerholz T, Simon P, Weiler N, Weyland A, Reinhart K, Brunkhorst FM, SepNet-Critical Care Trials G (2016) Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 316:1775–1785
    • View reference on publisher's website
  74. Gibbison B, Lopez-Lopez JA, Higgins JP, Miller T, Angelini GD, Lightman SL, Annane D (2017) Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care 21:78
    • View reference on publisher's website
  75. Cheng M, Pan ZY, Yang J, Gao YD (2014) Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care 59:557–563
    • View reference on publisher's website
  76. Briel M, Spoorenberg SMC, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, Gabarrus A, Blum CA, Confalonieri M, Kasenda B, Siemieniuk RAC, Boersma W, Bos WJW, Christ-Crain M (2018) Corticosteroids in Patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis 66:346–354
    • View reference on publisher's website
  77. Wu WF, Fang Q, He GJ (2018) Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. Am J Emerg Med 36:179–184
    • View reference on publisher's website
  78. Siempos II, Vardakas KZ, Kopterides P, Falagas ME (2008) Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 62:661–668
    • View reference on publisher's website
  79. Nie W, Zhang Y, Cheng J, Xiu Q (2012) Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS ONE 7:e47926
    • View reference on publisher's website
  80. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH (2015) Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163:519–528
    • View reference on publisher's website
  81. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S, Kaneko T (2015) Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep 5:14061
    • View reference on publisher's website
  82. Marti C, Grosgurin O, Harbarth S, Combescure C, Abbas M, Rutschmann O, Perrier A, Garin N (2015) Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS ONE 10:e0144032
    • View reference on publisher's website
  83. Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC (2016) Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 149:209–219
    • View reference on publisher's website
  84. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS (2016) Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 3:Cd010406
  85. Sibila O, Rodrigo-Troyano A, Torres A (2016) Nonantibiotic adjunctive therapies for community-acquired pneumonia (corticosteroids and beyond): where are we with them? Semin Respir Crit Care Med 37:913–922
    • View reference on publisher's website
  86. Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ (2007) A case series of macrolide treatment failures in community acquired pneumonia. J Chemother (Florence, Italy) 19:536–545
    • View reference on publisher's website
  87. Cilloniz C, Albert RK, Liapikou A, Gabarrus A, Rangel E, Bello S, Marco F, Mensa J, Torres A (2015) The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 191:1265–1272
    • View reference on publisher's website
  88. Yin YD, Wang R, Zhuo C, Wang H, Wang MG, Xie CM, She DY, Yuan X, Wang RT, Cao B, Liu YN (2017) Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study. J Thorac Dis 9:3774–3781
    • View reference on publisher's website
  89. Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS (2016) In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the united states. Antimicrob Agents Chemother 60:4407–4411
    • View reference on publisher's website
  90. Pfaller MA, Sader HS, Rhomberg PR, Flamm RK (2017) In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother 61:AAC-02609
  91. Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G (2017) Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug Des Dev Ther 11:3559–3566
    • View reference on publisher's website
  92. Liu Y, Zhang Y, Wu J, Zhu D, Sun S, Zhao L, Wang X, Liu H, Ren Z, Wang C, Xiu Q, Xiao Z, Cao Z, Cui S, Yang H, Liang Y, Chen P, Lv Y, Hu C, Lv X, Liu S, Kuang J, Li J, Wang D, Chang L (2017) A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. J Microbiol Immunol Infect Wei mian yu gan ran za zhi 50:811–820
  93. Amalakuhan B, Echevarria KL, Restrepo MI (2017) Managing community acquired pneumonia in the elderly—the next generation of pharmacotherapy on the horizon. Expert Opin Pharmacother 18:1039–1048
    • View reference on publisher's website
  94. Carreno JJ, Lodise TP (2014) Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE. Infect Dis Ther 3:123–132
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement